PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) Director Thomas M. Krummel sold 20,000 shares of PROCEPT BioRobotics stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director now owns 45,631 shares in the company, valued at $2,737,860. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
PROCEPT BioRobotics Stock Up 4.2 %
PRCT opened at $64.31 on Monday. The stock’s 50 day simple moving average is $50.25 and its 200-day simple moving average is $43.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.44 and a current ratio of 8.52. PROCEPT BioRobotics Co. has a 1 year low of $24.83 and a 1 year high of $64.89.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04. PROCEPT BioRobotics had a negative net margin of 66.12% and a negative return on equity of 41.35%. The company had revenue of $44.50 million during the quarter, compared to analysts’ expectations of $41.58 million. During the same quarter in the prior year, the company posted ($0.63) EPS. The business’s revenue was up 82.4% on a year-over-year basis. On average, analysts expect that PROCEPT BioRobotics Co. will post -1.96 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the company. Truist Financial raised their target price on PROCEPT BioRobotics from $63.00 to $72.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company boosted their target price on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $49.50.
Read Our Latest Report on PRCT
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Featured Articles
- Five stocks we like better than PROCEPT BioRobotics
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Metal Stocks Setting Up for Double-Digit Growth
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- 3 Small Caps With Big Return Potential
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.